Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on December 18, 2019. The registrant is a Delaware corporation headquartered in Alameda, California, and is classified as an emerging growth company. The filing discloses a specific financial event regarding a loan facility drawdown.
Key Financial Metrics
The filing details a specific debt transaction rather than comprehensive financial statements. Key metrics disclosed include:
- Debt Drawdown: An additional $1.3 million was drawn under a Loan Facility Agreement with Juvenescence Limited.
- Total Outstanding Principal: $1.8 million (comprising the new $1.3 million draw and a previous $500,000 draw).
- Repayment Date: February 15, 2021.
- Interest Terms: No cash interest accrues initially; instead, 19,000 shares of common stock were issued. If the loan is not repaid when due, interest accrues at 10% per annum, compounded daily.
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for these metrics.
Material Changes
The primary material change reported is the increase in the company's direct financial obligation by $1.3 million. This drawdown increases the total indebtedness under the August 13, 2019, Loan Agreement to $1.8 million. Additionally, the company issued 19,000 shares of common stock to the lender in lieu of accrued interest.
Guidance, Outlook, and Risks
Conversion Rights: The loan balance (principal and accrued interest) may be converted into AgeX common stock or "units" if the company consummates a "Qualified Offering" defined as a sale of common stock with gross proceeds of at least $7.5 million.
Events of Default: The lender may declare the loan immediately due and payable if an Event of Default occurs and remains uncured for 10 business days. Defined events include failure to pay, failure to perform obligations, incurring additional indebtedness over $100,000 (or $25,000 unpaid), insolvency, cessation of business, or a material adverse change in financial condition.
Forward-Looking Statements: The company includes standard disclaimers that actual results may differ materially from anticipated results due to various risk factors.
Investor Verification Checklist
- Verify the total outstanding debt balance of $1.8 million and the specific repayment deadline of February 15, 2021.
- Confirm the dilution impact of the 19,000 shares issued to Juvenescence Limited.
- Assess the company's ability to raise at least $7.5 million in a Qualified Offering to potentially convert the debt into equity.
- Review the full Loan Agreement (exhibit to the August 14, 2019, Form 10-Q) for detailed covenants and default triggers.
- Monitor the company's liquidity status to ensure it can meet the repayment obligation or trigger the conversion clause before the maturity date.